Analysts Have Conflicting Sentiments on These Healthcare Companies: CareDx (CDNA), Neurocrine (NBIX) and Viking Therapeutics (VKTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CareDx (CDNA – Research Report), Neurocrine (NBIX – Research Report) and Viking Therapeutics (VKTX – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CareDx (CDNA)
In a report released today, William Bonello from Craig-Hallum maintained a Hold rating on CareDx. The company’s shares closed last Thursday at $20.14.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for CareDx with a $18.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
Truist Financial analyst Danielle Brill maintained a Buy rating on Neurocrine today. The company’s shares closed last Thursday at $129.61.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $181.88, a 30.3% upside from current levels. In a report issued on January 28, TipRanks – xAI also upgraded the stock to Buy with a $152.00 price target.
Viking Therapeutics (VKTX)
Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics today. The company’s shares closed last Thursday at $33.53, close to its 52-week low of $24.41.
According to TipRanks.com, Lee is a 5-star analyst with an average return of
Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $89.44, which is a 205.3% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $75.00 price target.
